State Street
CGTX icon

State Street’s Cognition Therapeutics CGTX Stock Holding History

State Street’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$239K Hold
314,483
– – ﹤0.01% 3845
2025
Q4 		$425K Sell
314,483
-10,500
-3% -$17K ﹤0.01% 3722
2025
Q3 		$439K Buy
324,983
+203,133
+167% +$277K ﹤0.01% 3691
2025
Q2 		$37.7K Hold
121,850
– – ﹤0.01% 4132
2025
Q1 		$51.3K Hold
121,850
– – ﹤0.01% 4092
2024
Q4 		$85.5K Buy
121,850
+59,100
+94% +$29.2K ﹤0.01% 4021
2024
Q3 		$29.4K Hold
62,750
– – ﹤0.01% 4179
2024
Q2 		$104K Buy
62,750
+12,000
+24% +$23.9K ﹤0.01% 4003
2024
Q1 		$92.4K Hold
50,750
– – ﹤0.01% 4043
2023
Q4 		$93.9K Hold
50,750
– – ﹤0.01% 4067
2023
Q3 		$73.1K Buy
50,750
+20,500
+68% +$32.1K ﹤0.01% 4190
2023
Q2 		$55.4K Hold
30,250
– – ﹤0.01% 4394
2023
Q1 		$59.9K Hold
30,250
– – ﹤0.01% 4462
2022
Q4 		$63.5K Buy
30,250
+15,600
+106% +$31.5K ﹤0.01% 4497
2022
Q3 		$28K Buy
+14,650
New +$30.5K ﹤0.01% 4777

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

State Street's CGTX Position: Q1 2026 in Review

State Street held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 314,483 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3845.

State Street first reported a position in CGTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $439K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • State Street held 314,483 shares of Cognition Therapeutics worth $239K as of Q1 2026.
  • State Street left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3845 holding.
  • State Street first reported a position in Cognition Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • State Street's Cognition Therapeutics position peaked at $439K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.